MSME (Udyam registered) Ministry of MSME
- Category
- Small (2024-25)
- Udyam number
- UDYAM-DL-03-0009207
Accure Labs Private Limited - pharma in New Delhi, Delhi, India. FY 2026 financials & compliance.
Revenue · FY 2025
₹40.39 Cr
▼ 3% YoY
Net profit · FY 2025
₹7.46 Cr
Net margin 18.5%
EBITDA · FY 2025
₹11.68 Cr
EBITDA margin 28.9%
Authorised capital
₹16.1 Cr
Registered with MCA
Paid-up capital
₹1.4 Lakh
Issued & subscribed
Open charges
₹6.33 Cr
Satisfied ₹2 Cr
Company age
22 yrs
Est. 2004
Employees · EPFO
17
Provident fund records
About Accure Labs Private Limited
Data last updated:
Accure Labs Private Limited is a private limited company based in New Delhi, Delhi, India. It operates in the drug formulation and development segment of the pharmaceuticals sector. It was incorporated on 25 August 2004 and has been in existence for over 22 years.
The company is registered with the Registrar of Companies (ROC), Delhi, under CIN U24232DL2004PTC128617. Its GSTIN is 07AAECA9631J1ZI (Delhi). The company holds 4 GST registrations, of which 2 are active.
The company has an authorised share capital of ₹16.1 Cr and a paid-up capital of ₹1.4 Lakh. It is led by directors including Amitabh Ganguli and Sandeep Sharadaprasad Srivastava.
Its last annual general meeting (AGM) was held on 30 September 2024, and its latest financial statements are for the year ended 31 March 2024. The registered office is at Flat No.1406A 14th Floor Building No. 89 Hemkunth Chamber Nehru, Place, New Delhi, Delhi, India – 110019.
As per the financials filed for FY 2025, the company reported a revenue of ₹40.39 Cr, a decline of 3% compared to the previous year. For the same year it recorded a net profit of ₹7.46 Cr (net margin 18.5%) and EBITDA of ₹11.68 Cr (EBITDA margin 28.9%). Revenue has grown at a compounded annual rate (CAGR) of 16% over three years and 19% over five years.
The company has about 17 employees on its provident fund (EPFO) records. Its group structure includes 1 subsidiary.
The company is associated with 1 brand: Accure Labs. As per MCA filings, the company has open charges of ₹6.33 Cr and satisfied charges of ₹2 Cr on record. Court records list 10 cases involving the company, including 7 filed by the company and 3 filed against it; 2 cases are pending. The company has 8 deals on record (6 secondary share transfers, 2 funding rounds), with disclosed funding of ₹14.91 Cr; the latest was in November 2022.
Accure Labs Private Limited is registered as a small enterprise under the Udyam registration framework (Reg. No. UDYAM-DL-03-0009207). The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website accurelabs.com.
Company details
CIN U24232DL2004PTC128617
Registration Number 128617
Incorporation Date 25 August 2004
ROC Delhi
Listing Status Unlisted
Company Status Active
Date of Last AGM 30 September 2024
Date of Balance Sheet 31 March 2024
Compliance Status Active Compliant
MSME Classification Small
Udyam Registration UDYAM-DL-03-0009207
Recognitions & Rankings of Accure Labs
Contact details
Accure Labs Private Limited's registered office is in New Delhi, Delhi. Its website is accurelabs.com. Its e-mail address and telephone number are in the company report.
- Email
- Telephone
- Website
- Social Media
- Registered AddressFlat No.1406A 14th Floor Building No. 89 Hemkunth Chamber Nehru, Place, New Delhi, Delhi, India – 110019
- IndustryPharma, Drug Formulation & Development
To see the full contact details of Accure Labs Private Limited, buy the company report.
Comprehensive company report
Accure Labs Private Limited - one report that includes everything
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
₹799 ₹999 20% off excluding 18% GST
Secure checkout · GST invoice included
Brands
Accure Labs operates one associated brand: Accure Labs. Each brand links to its own profile.
| Brand | Description | Website |
|---|---|---|
| Development and supply of generic pharmaceuticals and related services. | accurelabs.com |
Business activity
The main business activity of Accure Labs is trade. In detail, this covers retail trading.
| Main activity group code | Main activity | Business activity code | Business activity | Share of turnover |
|---|---|---|---|---|
| G | Trade | G2 | Retail Trading |
To see the full business activity and turnover split of Accure Labs Private Limited, buy the company report.
Financials of Accure Labs Private Limited
FY 2024 filings availableAccure Labs Private Limited reported revenue of ₹40.39 Cr (down 3% YoY) for FY 2025.
Revenue · FY 2025
₹40.39 Cr ▼ 3%
Net profit · FY 2025
₹7.46 Cr margin 18.5%
EBITDA · FY 2025
₹11.68 Cr margin 28.9%
Compounded Annual Growth Rate (CAGR)
Revenue CAGR growth
1 year
▼ 3%
3 years · compounded
▲ 16%
5 years · compounded
▲ 19%
EBITDA CAGR growth
1 year
▼ 1%
5 years · compounded
▲ 6%
Revenue fell 3% in the latest year, but over five years it has grown at a compounded annual rate (CAGR) of 19%. EBITDA fell 1% in the latest year. Three- and five-year figures are compounded annual growth rates (CAGR): the steady yearly rate that links the first and the last year. All are worked out from the filed statements.
Financial Statement Summary
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profit and Loss Statement | |||||
| Revenue from Operations | |||||
| Other Income | |||||
| Total Revenue | |||||
| Cost of Materials Consumed | |||||
| Employee Benefit Expense | |||||
| Finance Costs | |||||
| Depreciation and Amortisation | |||||
| Other Expenses | |||||
| Total Expenses | |||||
| EBITDA | ₹11.68 Cr | ||||
| Profit Before Tax | |||||
| Tax Expense | |||||
| Net Profit (PAT) | ₹7.46 Cr | ||||
| Balance Sheet | |||||
| Share Capital | |||||
| Reserves and Surplus | |||||
| Net Worth (Total Equity) | |||||
| Long-term Borrowings | |||||
| Short-term Borrowings | |||||
| Trade Payables | |||||
| Total Liabilities | |||||
| Fixed Assets | |||||
| Investments | |||||
| Inventories | |||||
| Trade Receivables | |||||
| Cash and Bank Balance | |||||
| Total Assets | |||||
Financial Ratios
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profitability | |||||
| EBITDA Margin | 28.9% | ||||
| Net Profit Margin | 18.5% | ||||
| Return on Equity (ROE) | |||||
| Return on Capital Employed (ROCE) | |||||
| Return on Assets (ROA) | |||||
| Liquidity and Debt | |||||
| Current Ratio | |||||
| Quick Ratio | |||||
| Debt-to-Equity Ratio | |||||
| Interest Coverage Ratio | |||||
| Efficiency and Growth | |||||
| Asset Turnover | |||||
| Receivable Days | |||||
| Payable Days | |||||
| Inventory Days | |||||
| Revenue Growth | |||||
| Net Profit Growth | |||||
To see the full financial statements and ratios of Accure Labs Private Limited, buy the company report.
Board of directors of Accure Labs Private Limited
Accure Labs has 4 current directors and 15 former directors. Current directors are listed first, with their designation and appointment date.
Current Directors
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Amitabh Ganguli | Director | 25 Apr 2019 | 7 Years 6 Months | Current |
| Sandeep Sharadaprasad Srivastava | Director | 17 Jul 2020 | 6 Years 3 Months | Current |
| Ratan Capoor | Director | 07 Oct 2022 | 4 Years 0 Months | Current |
| Jagrato Roy Also directs: Jyotsna Lamps Caps Private Limited, Octagon Distributors Private Limited, J.S. Got Tea Hospitality LLP and 1 more | Director | 29 May 2020 | 6 Years 4 Months | Current |
Auditor
Accure Labs Private Limited is audited by SINGHI & CO. for the financial year 2023.
| Auditor firm | Financial year | Firm registration number |
|---|---|---|
| SINGHI & CO. | FY 2023 | 302049E |
Shareholding
The shareholding of Accure Labs Private Limited is on record for 5 financial years, the latest being FY 2023, split between promoters, domestic institutions, foreign institutions, public shareholders and others.
| Shareholder category | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|
| Promoters | |||||
| Domestic institutional investors (DII) | |||||
| Foreign institutional investors (FII) | |||||
| Public | |||||
| Others |
To see the full shareholding pattern of Accure Labs Private Limited, buy the company report.
Charges & borrowings
Open charges
₹6.33 Cr
Satisfied charges
₹2 Cr
Breakdown by lending institutions
Latest charge details
| Date | Charge ID | Lender | Amount | Status | Modified or satisfied on |
|---|---|---|---|---|---|
| 13 Aug 2019 | 100283032 | The Hongkong and Shanghai Banking Corporation Limited | ₹6.33 Cr | Open | |
| 28 Apr 2023 | 100723030 | Hdfc Bank Limited | ₹2 Cr | Satisfied |
To see the full charge records of Accure Labs Private Limited, buy the company report.
Total charge records: 2 View all charges
Deals & funding
Accure Labs Private Limited has 8 deals on record (6 secondary share transfers, 2 funding rounds), with disclosed funding of ₹14.91 Cr; the latest was in November 2022.
Total deals
8
Secondary share transfers
6
Funding rounds
2
Disclosed funding
₹14.91 Cr
Deals on record (5 of 8)
| When | Deal | Amount | Parties |
|---|---|---|---|
| Nov 2022 | Secondary share transfer | Undisclosed | Buyer: 2 individuals Seller: an individual |
| Mar 2022 | Secondary share transfer | Undisclosed | Seller: Basix Promoters Private Limited , Sanyukta Developers Private Limited |
| Jul 2021 | Secondary share transfer | Undisclosed | Buyer: Wisdom Investment Private Limited Seller: an individual |
| Apr 2020 | Secondary share transfer | Undisclosed | Buyer: an individual Seller: an individual |
| Mar 2020 | Secondary share transfer | Undisclosed | Buyer: 2 individuals Seller: 2 individuals |
To see the full deal history of Accure Labs Private Limited, buy the company report.
Deal records are compiled from filings and public sources; amounts are shown only where the source reported them.
Legal cases
Accure Labs Private Limited has 10 court cases on record: 7 filed by Accure Labs, 3 filed against it. 2 cases are pending and 8 are disposed.
Total cases
10
Filed by the company
7
Filed against the company
3
Pending
2
Disposed
8
Cases by court
| Court | Cases | Against the company | Pending |
|---|---|---|---|
| District courts | 4 | 3 | 2 |
| Supreme Court | 4 | 0 | 0 |
| High courts | 2 | 0 | 0 |
Cases on record (5 of 10)
| Court | Type of case | Party | Status |
|---|---|---|---|
| Supreme Court | Court case (-Ordinary Civil Matters) | Filed by the company against Bristol-Myers Squibb India Private Limited Through Authorised Representative the Indiabulls Finance Centre 6Th Floor, Tower 1, Senapati Bapat Marg Elphinstone(W) Mumbai 400013 , , Maharashtra and 6 others | Disposed |
| Supreme Court | Court case (2804-Mercantile Laws, Commercial Transactions Including Banking : Trade Marks/Copy Rights/Patents/Design Act) | Filed by the company against Pfizer Products India Pvt. Ltd. Authorized Signatory Authorized Signatory Pfizer Centre, Patel Estate, S.V. Road , District: Jogeshwari (W) ,Mumbai , Maharashtra and 2 others | Disposed |
| District court, KHAIRTAL TIJARA, Rajasthan | Criminal case | Filed against the company by State | Pending |
| District court, Gautam Buddha Nagar, Uttar Pradesh | Civil suit | Filed by the company against an individual | Pending |
| High Court of Delhi | Writ petition | Filed by the company against Union of India & Ors. | Disposed |
To see the full case history of Accure Labs Private Limited, buy the company report.
Case records are compiled from court listings and may lag the court's own records. A case filed against a company is not a finding against it.
MSME payment delays
No delayed payments to MSME suppliers are on our record for Accure Labs Private Limited; the supplier-wise MSME Form 1 check is in the company report Buy the company report.
Group structure & subsidiaries
Accure Labs has 1 subsidiary company. This group structure data is as of FY 2023. The table lists each entity with its relationship and holding.
1
Subsidiary companies
Key subsidiaries
| Company Name | CIN | Shares held |
|---|---|---|
| Eurasian Minerals & Enterprises Private Limited | U74120DL2007PTC163763 |
To see the full group structure of Accure Labs Private Limited, buy the company report.
Employees & EPFO
Accure Labs Private Limited has a workforce of 17 employees on its EPFO records as of Mar 22, 2024, across 1 active EPFO establishment.
Employee count
17
Active EPFO establishments
1
GST
Accure Labs has 4 GST registrations: 2 active and 2 cancelled or inactive.
Total GSTINs
4
Active
2
Cancelled / inactive
2
| GSTIN | State | Status | Registered on |
|---|---|---|---|
| 07AAECA9631J1ZI | Delhi | Active | 01 Jul 2017 |
| 09AAECA9631J2ZD | Uttar Pradesh | Active | 21 Nov 2019 |
To see the full GST registrations and return filing status of Accure Labs Private Limited, buy the company report.
Recent activity
Accure Labs Private Limited has 17 board changes on record since 2014: 4 appointments and 13 cessations. The latest: Ratan Capoor ceased to be Additional Director on 29 Sep 2023.
Charges
A charge with The Hongkong And Shanghai Banking Corporation Limited of Rs. 6.33 Cr registered on 13 Aug 2019 with Charge ID 100283032 was modified on 21 Aug 2025.
AGM
Accure Labs Private Limited last Annual general meeting of members was held on 30 Sep 2024 as per latest MCA records.
Charges
A charge registered on 28 Apr 2023 via Charge ID 100723030 with Hdfc Bank Limited was fully satisfied on 01 Jun 2024.
Filing
Accure Labs Private Limited has filed its annual Financial statements for the year ended 31 Mar 2024 with Roc Delhi.
Ceased
Ratan Capoor ceased to be Additional Director.
Charges
A charge with Hdfc Bank Limited amounted to Rs. 2.00 Cr with Charge ID 100723030 was registered on 28 Apr 2023.
Ceased
Moushumi Roy ceased to be Director.
Appointed
Ratan Capoor was appointed as Director.
Ceased
Garima Capoor ceased to be Director.
Ceased
Khanish Juneja ceased to be Company Secretary.
Ceased
Jagrato Roy ceased to be Additional Director.
Ceased
Sandeep Sharadaprasad Srivastava ceased to be Additional Director.
12 earlier events are in the company report.
Frequently asked questions
Accure Labs is an active private limited company based in New Delhi, Delhi, India. The company works in drug formulation and development, within the pharma industry. It was incorporated on 25 August 2004 (22+ years old) and is registered under CIN U24232DL2004PTC128617.
Accure Labs has 4 current directors:
- Amitabh Ganguli - Director
- Sandeep Sharadaprasad Srivastava - Director
- Ratan Capoor - Director
- Jagrato Roy - Director
The latest financial statements of Accure Labs on record with the MCA are for the year ended 31 March 2024. Its last annual general meeting was held on 30 September 2024. Year-wise statements from 2015 are in the company report.
The GSTIN of Accure Labs is 07AAECA9631J1ZI, registered in Delhi. The company has 4 GST registrations in all, of which 2 are active and 2 are cancelled or inactive. Other active GSTINs include 09AAECA9631J2ZD (Uttar Pradesh).
The CIN (Corporate Identification Number) of Accure Labs is U24232DL2004PTC128617. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Accure Labs has 10 court cases on record: 7 filed by the company and 3 filed against it. 2 are pending. Most are in the district courts.
Accure Labs was incorporated on 25 August 2004, making it 22+ years old. It is registered with the Registrar of Companies, Delhi.
Accure Labs has 8 deals on record (6 secondary share transfers, 2 funding rounds), with disclosed funding of ₹14.91 Cr; the latest was in November 2022.
Ratan Capoor ceased to be Additional Director on 29 Sep 2023. Moushumi Roy ceased to be Director on 30 Nov 2022. Ratan Capoor was appointed as Director on 07 Oct 2022. Accure Labs has 17 board changes on record in total.
Yes, Accure Labs is registered as a small enterprise under Udyam registration (number: UDYAM-DL-03-0009207).